Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant for idiopathic and Parkinson's disease-related REM sleep behavior disorder
ChiCTR2600133902Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of daridorexant in REM sleep behavior disorder (RBD) and Isolated REM Sleep Behavior Disorder (iRBD) (5 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Change in REM sleep without atonia index from baseline to week 12. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
daridorexant
03
Conditions
REM sleep behavior disorder (RBD)Isolated REM Sleep Behavior Disorder (iRBD)
Beyond the preview
Go deeper on ChiCTR2600133902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133902.